Summary
54 / 100 · Bulios Score
What speaks for it
- It could repay all its net debt from 0.8 years of operating profit.
- It passes 8 of the 9 points of the Piotroski financial health test.
What to watch
- The share price is above the Bulios Fair Price.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 43.7 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue fell by 4.9% a year over 5 years. Over the last 3 years it grew by 7.4% a year.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 58 USD
- Research and development 6.6 USD
- Sales and administration 21 USD
- Taxes and other 4.1 USD
- Net profit 11 USD
Net profit, industry median (Hardware, Equipment & Parts) 6.6 USD
Out of every 100 USD of revenue, 11 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.4 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 7
- Hold 6
- Sell 2
Today's price within the analysts' price targets
The average target of $40.67 is 21% above today's price. 47% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Precision Devices 55%
- MedTech & Specialty Audio 45%
By region
- UNITED STATES 42%
- Asia 38%
- Europe 16%
- Other Americas 2.0%
- Other Geographical Locations Member 1.8%
Precision Devices brings in 55% of revenue.
Segments in detail